This follows the FDA's stated plan to support scientific research related to regenerative medicine and a policy framework to promote the approval of legitimate regenerative medicine products but, at the same time, to initiate enforcement actions against clinics marketing products using unapproved manufacturing protocols. In the FDA news release, FDA Commissioner Scott Gottlieb stated, ''Cell-based regenerative medicine holds significant medical opportunity, but we've also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patient's health at risk.'' He furthermore stated, ''In some instances, patients have suffered serious and permanent harm after receiving these unapproved products.'' These clinics had received warning letters from the FDA but failed to come into compliance with the law, leading to the enforcement actions.
What does this mean for us sports medicine practitioners? The topic of biologic augmentation of soft tissue healing continues to be of significant interest to sports medicine specialists and readers of the American Journal of Sports Medicine. The journal has become an important source of rigorous information in this area. Over the last year, the FDA has focused increased attention on ''regenerative medicine,'' and here I provide an update on the current status and recent guidelines in this area.
RECENT FDA GUIDELINES
Most ''biologics'' / regenerative medicine products are regulated under 21 CFR 1271 (title 21 of the Code of Federal Regulations, part 1271). There are 2 distinctly different designations under part 1271: section 361, which is reserved for tissues that are ''minimally manipulated'' and intended only for homologous use, and section 351, used for a new drug or biologic product that requires FDA premarket review (''investigational new drug'' or ''investigational device exemption''). Currently utilized ''stem cell'' preparations derived from autologous bone marrow or adipose tissue have traditionally been regulated under section 361. However, recently finalized guidance documents to physicians and industry place products from adipose tissue on notice, implying that an injection created by mechanically processed lipoaspirate for orthopaedic indications is not considered homologous use or minimal manipulation by the FDA.
The FDA has focused increased scrutiny on the evergrowing number of regenerative medicine clinics in the United States that offer biologic therapy for an implausible number and variety of conditions. These therapies are being provided for conditions where very few data support their use and significant complications have occurred. Furthermore, some unscrupulous practitioners charge very high costs for these unproven therapies. At the same time, it is recognized that there is great potential for the ability to biologically augment healing and regenerate tissues.
To address these issues, an FDA guidance document released November 16, 2017, put forth 2 major directives: (1) identify and prosecute unscrupulous regenerative medicine clinics and (2) streamline the approval pathway for legitimate therapies. In this document, the FDA commissioner stated, ''We're at the beginning of a paradigm change in medicine with the promise of being able to facilitate regeneration of parts of the human body, where cells and tissues can be engineered to grow healthy, functional organs to replace diseased ones; new genes can be introduced into the body to combat disease; and adult stem cells can generate replacements for cells that are lost to injury or disease. '' 4 This document further stated, ''This field is dynamic and complex. As such, it has presented unique challenges to researchers, health care providers, and the FDA as we seek to provide a clear pathway for those developing new therapies in this promising field, while making sure that the FDA meets its obligation to ensure the safety and efficacy of the medical products that patients rely upon.'' The guidelines provide a 36-month time frame for manufacturers of biologics and regenerative medicine products to come into compliance. Some manufacturers have already received warning letters from the FDA citing future ramifications if their processes fall outside the new guidelines. The overall purpose of these guideline is to protect patients from products that pose potential risks, while accelerating access to safe and effective new therapies.
This important guidance document also clarified the FDA's view of minimal manipulation and homologous use. The FDA defined minimal manipulation as processing that does not alter the relevant biological characteristics of cells or tissues. Importantly, this meant that laboratory- based cell sorting and culture expansion are not allowed. The homologous use criterion has been a frequent source of confusion for manufacturers. A cell therapy product was considered homologous if it performed the same basic function or functions in the recipient as in the donor. This can be confusing, since a given cell or tissue source may have a structural and/or metabolic function. The concepts of minimal manipulation and homologous use are critical to understanding the FDA's stance on regulation of biologic products. Careful reading of the guidance document makes clear that some currently used products will fall outside the guidelines and will require application through the investigational new drug process. Some examples from the document follow 2 :
''A manufacturer recovers adipose tissue by tumescent liposuction and processes (eg, enzymatically digests, mechanically disrupts, etc) the adipose tissue to isolate cellular components (with or without subsequent cell culture or expansion), commonly referred to as stromal vascular fraction. . . . In this example, the HCT/P [human cells, tissues, and cellular and tissue-based product] generally is considered more than minimally manipulated.'' ''An HCT/P from adipose tissue is used to treat musculoskeletal conditions such as arthritis or tendonitis by regenerating or promoting the regeneration of articular cartilage or tendon. This is generally not considered a homologous use because regenerating or promoting the regeneration of cartilage or tendon is not a basic function of adipose tissue.'' ''An amniotic membrane product is used for wound healing and/or to reduce scarring and inflammation. This is not homologous use because wound healing and reduction of scarring and inflammation are not basic functions of amniotic membrane.'' The 21st Century Cures Act was signed into law December 2016. One important purpose of this legislation is to support and encourage development in the area of regenerative medicine.
1 The 21st Century Cures Act created a new designation geared toward regenerative medicine technologies intended to expedite the process by which new drugs and devices are approved by easing the requirements for FDA approval of new products or new indications for existing drugs. One result of the 21st Century Cures Act has been the development of ''Standards for Regenerative Medicine and Regenerative Medicine Advanced Therapies'' (section 3036). This document provides guidance and mechanisms for accelerated approval for regenerative medicine advanced therapy products. A drug is eligible for such designation if the drug is a ''regenerative medicine therapy,'' defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product based on such therapies or products that is not currently regulated under section 361. Further important definitions are that the drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease. Orthopaedics may benefit from having the FDA recognize conditions such as osteoarthritis as a ''serious disease or condition,'' which is a position that can be supported by the well-documented costs and functional disability related to osteoarthritis of the knee, for example.
The regulations promulgated under 21 CFR 1271 do not apply when done during the ''same surgical procedure.'' The FDA's view is that ''autologous cells or tissues that are removed from an individual and implanted into the same individual without intervening processing steps beyond rinsing, cleansing, sizing, or shaping, raise no additional risks of contamination and communicable disease transmission beyond that typically associated with surgery.'' 3 Limited tissue handling, including rinsing and cleansing by centrifugation or filtration solely to remove debris (eg, lipids, blood), would allow the HCT/P to qualify for the same procedure exemption. However, other processing steps-including those by centrifugation or filtration for cell isolation, cell expansion, cell activation, or enzymatic digestion-would generally not allow the material to qualify for the exception. These rules affect the use of adipose tissue, which is being used with increasing frequency in sports medicine applications. For example, the guidelines state that centrifugation of adipose tissue is allowed and qualifies for the ''same surgical procedure'' exception, while enzymatic digestion or mechanical disruption would not allow for the exception. There are products currently in use in the United States that use mechanical disruption of lipoaspirate. Such products may need to apply for investigational new drug status based on the new guidelines. As patients increasingly inquire about and demand the use of stem cells and other biologic therapies, we as clinicians need to keep a careful eye on the evolving regulatory environment.
SUMMARY
It is clear that biologic therapies hold great promise and potential in the area of orthopaedic sports medicine. The tremendous heterogeneity in various minimally manipulated formulations has led to confusion and sometimes unpredictable outcomes. Given this environment, the FDA and other regulatory bodies will continue to provide guidance in this area, and it behooves orthopaedic sports medicine practitioners interested in this area to carefully follow this evolving landscape. Sports medicine practitioners should be aware of the current FDA stance on the various minimally manipulated formulations, understanding that some currently used preparations may ultimately be removed from the market until they undergo a formal investigational new drug process. Other countries have different regulations; thus, practitioners in other countries may be able to use products and techniques that are not available in the United States. I would encourage practitioners in other countries who use cell therapies that are not available in the United States to carefully evaluate their patients and report the data.
In response to the widespread use of uncharacterized minimally manipulated products, a recent meeting was organized by the American Academy of Orthopaedic Surgeons in conjunction with the National Institutes of Health (AAOS/NIH U-13 Conference: Optimizing Clinical Use of Biologics in Orthopedic Surgery; February 15-17, 2018) that brought together basic scientists, clinicians, experts in clinical research, regulatory officials, and patient advocates to review the current status of minimally manipulated formulations and to identify the critical research questions for the field. A white paper will summarize the proceedings from the meeting and define a research agenda to guide the field. Scott A. Rodeo, MD New York, New York, USA
